Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
Nathalie Jacque(Institut Cochin), Didier Bouscary(Université Paris Cité), Clément Larrue(Centre National de la Recherche Scientifique), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Susan D. Demo(Calithera (United States)), Anne Marie Ronchetti(Inserm), Rudy Birsen(Centre National de la Recherche Scientifique), Patrick Mayeux(Université Paris Cité), Mireille Lambert(Inserm), Pierre Sujobert(Université Claude Bernard Lyon 1), Thiago Trovati Maciel(Inserm), Nicolas Chapuis(Délégation Paris 5), Laury Poulain(Inserm), Ivan Cruz Moura(Inserm), Justine Decroocq(Centre National de la Recherche Scientifique), Estelle Saland(Université Toulouse III - Paul Sabatier), Catherine Lacombe(Centre National de la Recherche Scientifique), Laure Joseph(Inserm), Jean Emmanuel Sarry(Université Toulouse III - Paul Sabatier), Jérôme Tamburini(Centre National de la Recherche Scientifique), Godelieve Meunier(Inserm), Lise Willems(Hôpital Cochin)
Cited by 383
Related Papers
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
|Cancer Research|2007|671
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
|Blood|2013|357
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
|Haematologica|2009|316